Artivion’s first quarter results for 2026 were met with a significant negative market reaction, with investors responding to shortfalls in adjusted profitability and a guidance revision for the year. Management attributed these results to lower-than-expected stent graft sales, particularly in international markets and the U.S., as well as delays in AMDS starter set sales due to hospital procurement hurdles. CEO Pat Mackin acknowledged, “There were two things that did not go as planned in the first quarter,” specifically highlighting international stent softness and challenges with AMDS starter set adoption.
Is now the time to buy AORT? Find out in our full research report (it’s free for active Edge members).
Artivion (AORT) Q1 CY2026 Highlights:
- Revenue: $116.3 million vs analyst estimates of $115.9 million (17.5% year-on-year growth, in line)
- Adjusted EPS: $0.08 vs analyst expectations of $0.12 (35.1% miss)
- Adjusted EBITDA: $22.08 million vs analyst estimates of $22.96 million (19% margin, 3.8% miss)
- The company dropped its revenue guidance for the full year to $488 million at the midpoint from $495 million, a 1.4% decrease
- EBITDA guidance for the full year is $103.5 million at the midpoint, below analyst estimates of $106.5 million
- Operating Margin: 5%, up from 2.2% in the same quarter last year
- Market Capitalization: $1.08 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Artivion’s Q1 Earnings Call
- Stifel: asked if the revised guidance was conservative and how PMA approval for AMDS would impact the sales ramp; CEO Pat Mackin noted guidance accounts for current trends and that PMA approval should reduce hospital barriers but will take time to translate into sales.
- Lake Street Capital (Frank Takkinen): questioned whether new AMDS account growth was plateauing or if reordering was lagging; Mackin clarified that existing account reorders exceeded expectations, while new account additions are hindered by upfront costs and IRB requirements.
- Canaccord Genuity (William Plovanic): inquired about strategies to overcome AMDS starter set resistance and if consignment was an option; COO Lance Berry said consignment was not the preferred route and stressed ongoing efforts to address purchase barriers.
- Oppenheimer: asked how many accounts were deferring AMDS purchases until PMA approval and if a backlog would create a surge post-approval; Mackin indicated a number of accounts are waiting, and a bump in sales is expected once approval is granted.
- Freedom Capital Markets: sought clarity on On-X adoption among different patient segments post-new clinical data; Mackin reported most growth is in patients aged 50-65, with ongoing efforts to expand share in the bioprosthetic segment.
Catalysts in Upcoming Quarters
In the coming quarters, our team will be monitoring (1) the timing and commercial impact of AMDS’s PMA approval, (2) progress toward closing and integrating the Endospan acquisition, and (3) evidence of stabilization or improvement in international stent graft sales and supply chain resolution. The pace of clinical trial enrollment and updates on key product launches will also be important indicators.
Artivion currently trades at $22.88, down from $35.42 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).
Our Favorite Stocks Right Now
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
